These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 21062648)
1. What can be concluded from the ERSPC and PLCO trial data? Studer UE; Collette L Urol Oncol; 2010; 28(6):668-9. PubMed ID: 21062648 [TBL] [Abstract][Full Text] [Related]
2. PSA-based screening for prostate cancer. Too many adverse effects. Prescrire Int; 2012 Sep; 21(130):215-7. PubMed ID: 23016259 [TBL] [Abstract][Full Text] [Related]
3. ERSPC and PLCO prostate cancer screening studies: what are the differences? Schröder FH; Roobol MJ Eur Urol; 2010 Jul; 58(1):46-52. PubMed ID: 20362385 [No Abstract] [Full Text] [Related]
4. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Schröder FH Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157 [TBL] [Abstract][Full Text] [Related]
5. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Luján M; Páez A; Pascual C; Angulo J; Miravalles E; Berenguer A Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893 [TBL] [Abstract][Full Text] [Related]
6. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial]. Richard F Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381 [No Abstract] [Full Text] [Related]
7. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK; J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007 [TBL] [Abstract][Full Text] [Related]
8. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134 [TBL] [Abstract][Full Text] [Related]
9. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Roobol MJ; Zappa M; Määttänen L; Ciatto S Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912 [TBL] [Abstract][Full Text] [Related]
10. PSA and prostate cancer screening: the challenge of the new millennium. Bjartell A Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305 [No Abstract] [Full Text] [Related]
11. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Hernández J; Thompson IM Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895 [TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Roobol MJ; Kranse R; de Koning HJ; Schröder FH Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478 [TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Schröder FH Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Vutuc C; Schernhammer ES; Haidinger G; Waldhör T Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872 [TBL] [Abstract][Full Text] [Related]
15. Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies. Ilic D Recent Results Cancer Res; 2014; 202():65-71. PubMed ID: 24531779 [TBL] [Abstract][Full Text] [Related]
16. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831 [TBL] [Abstract][Full Text] [Related]
17. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality. Höltl W; Lunglmayr G Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868 [No Abstract] [Full Text] [Related]
18. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault]. Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380 [TBL] [Abstract][Full Text] [Related]
19. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Roobol MJ; Roobol DW; Schröder FH Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]